Noema Pharma Appoints Michael Samar as Chief Financial Officer
January 08, 2025 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development
December 18, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
Noema Pharma Announces First Patients Dosed in Phase 2b Study with Gemlapodect (NOE-105), a First-In-Class Investigational Therapy for Tourette Syndrome
October 30, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study...
Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints
October 17, 2024 08:00 ET
|
Noema Pharma AG
– Topline results from Phase 2a study – Nearly 60% of all patients treated with gemlapodect and 88% of patients completing the study at the target clinical dose range were responders based on the...
Noema Pharma Announces Completion of Enrollment for GALENE Phase 2B Trial Evaluating NOE-101, a First-in-Class mGluR5 NAM, for Seizure Control in Tuberous Sclerosis Complex
August 13, 2024 08:00 ET
|
Noema Pharma AG
-- Top-line results from Phase 2B study expected in first quarter of 2025 -- BASEL, Switzerland, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting...
Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause
May 22, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, May 22, 2024 (GLOBE NEWSWIRE) -- Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been...
Noema Pharma to Present at Two Upcoming Conferences
January 03, 2024 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that members of...
Noema Pharma Appoints Robert Lasser, M.D., as Chief Medical Officer
November 15, 2023 08:00 ET
|
Noema Pharma AG
BASEL, Switzerland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced Robert Lasser,...
Noema Pharma Appoints Ilise Lombardo, M.D., as Chief Executive Officer
June 21, 2023 07:00 ET
|
Noema Pharma AG
BASEL, Switzerland, June 21, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced the appointment of...
Noema Pharma to Present at BioEquity Europe 2023
May 09, 2023 07:00 ET
|
Noema Pharma AG
BASEL, Switzerland, May 09, 2023 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, today announced that senior members...